P/E ratio for Repligen (RGEN)

P/E ratio history for Repligen from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novavax NVAX	-0.8317	-101.33%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	87.7	40.07%	🇺🇸 USA
Neurocrine Biosciences NBIX	55.3	-11.78%	🇺🇸 USA
General Electric GE	23.4	-62.70%	🇺🇸 USA
Thermo Fisher Scientific TMO	31.9	-49.10%	🇺🇸 USA
Bristol-Myers Squibb BMY	15.0	-76.03%	🇺🇸 USA
Pfizer PFE	13.3	-78.80%	🇺🇸 USA
Bio-Techne TECH	37.2	-40.64%	🇺🇸 USA
Sangamo Therapeutics SGMO	-0.4536	-100.72%	🇺🇸 USA
Charles River Laboratories CRL	15.7	-74.89%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.